Marxsa schreef op 3 juni 2020 10:36:
[...]
Zoals gezegd even uit mijn hoofd Bassie.
Voor de volledigheid:
We have increased our valuation for Pharming from EUR 2.0 billion to EUR 2.1 billion. This is
based on a further increase of profits and revenues from RUCONEST® as well as the ongoing
development of its late stage pipeline including leniolisib. We have now also put a value on
other programs in clinical development like pre-eclampsia and contrast induced nephropathy
(CIN) Furthermore, we expect Pompe's Disease to be in the clinic in the near future. This
translates based on the fully diluted number of 742 million shares into EUR 2.84 per share.
nebula.wsimg.com/22f4a4972f988a512c0e...